The phase Ⅲ clinical trial of Tyroserleutide is conducting at 24 leading liver cancer treatment Tier-3 hospitals in China. Due to the changes of some Clinical Research Assistants (CTA) and their directly leaders, as well as in order to facilitate the subjects enrollment, the training was held by the project team at the headquarters of CMS on February 25th, 2013. Totally 9 CTAs, 3 directly clinal trial responsible persons and other project-related personnels attended the training.
The training was planned and prepared by Shenzhen Kangzhe Medical Research and Development Department. The Vice-president of Shenzhen Kangzhe, Marketing Director and Director of Tyroserleutide Project, Ms. Sa Manlin represented CMS to give a speech, she emphasized the importance of CTA of this clinical trial. The Medical Research and Development Department introduced the clinical trial operation in details. After the training, Ms. Sa Manlin issued a certificate for the qualified personnels.
Through the training, new CTAs can effectively master the operation procedures and standards of the clinical trial, which laid a solid foundation for smooth progress and completion of the clinical trial